Assessment of androgen receptor expression in breast cancer patients using 18 F-FDG PET/CT radiomics and clinicopathological characteristics
© 2023. The Author(s)..
OBJECTIVE: In the present study, we mainly aimed to predict the expression of androgen receptor (AR) in breast cancer (BC) patients by combing radiomic features and clinicopathological factors in a non-invasive machine learning way.
MATERIALS AND METHODS: A total of 48 BC patients, who were initially diagnosed by 18F-FDG PET/CT, were retrospectively enrolled in this study. LIFEx software was used to extract radiomic features based on PET and CT data. The most useful predictive features were selected by the LASSO (least absolute shrinkage and selection operator) regression and t-test. Radiomic signatures and clinicopathologic characteristics were incorporated to develop a prediction model using multivariable logistic regression analysis. The receiver operating characteristic (ROC) curve, Hosmer-Lemeshow (H-L) test, and decision curve analysis (DCA) were conducted to assess the predictive efficiency of the model.
RESULTS: In the univariate analysis, the metabolic tumor volume (MTV) was significantly correlated with the expression of AR in BC patients (p < 0.05). However, there only existed feeble correlations between estrogen receptor (ER), progesterone receptor (PR), and AR status (p = 0.127, p = 0.061, respectively). Based on the binary logistic regression method, MTV, SHAPE_SphericityCT (CT Sphericity from SHAPE), and GLCM_ContrastCT (CT Contrast from grey-level co-occurrence matrix) were included in the prediction model for AR expression. Among them, GLCM_ContrastCT was an independent predictor of AR status (OR = 9.00, p = 0.018). The area under the curve (AUC) of ROC in this model was 0.832. The p-value of the H-L test was beyond 0.05.
CONCLUSIONS: A prediction model combining radiomic features and clinicopathological characteristics could be a promising approach to predict the expression of AR and noninvasively screen the BC patients who could benefit from anti-AR regimens.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
---|---|
Enthalten in: |
BMC medical imaging - 23(2023), 1 vom: 17. Juli, Seite 93 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Jia, Tongtong [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 24.07.2023 Date Revised 25.07.2023 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1186/s12880-023-01052-z |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM359615406 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM359615406 | ||
003 | DE-627 | ||
005 | 20231226081244.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s12880-023-01052-z |2 doi | |
028 | 5 | 2 | |a pubmed24n1198.xml |
035 | |a (DE-627)NLM359615406 | ||
035 | |a (NLM)37460990 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Jia, Tongtong |e verfasserin |4 aut | |
245 | 1 | 0 | |a Assessment of androgen receptor expression in breast cancer patients using 18 F-FDG PET/CT radiomics and clinicopathological characteristics |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 24.07.2023 | ||
500 | |a Date Revised 25.07.2023 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023. The Author(s). | ||
520 | |a OBJECTIVE: In the present study, we mainly aimed to predict the expression of androgen receptor (AR) in breast cancer (BC) patients by combing radiomic features and clinicopathological factors in a non-invasive machine learning way | ||
520 | |a MATERIALS AND METHODS: A total of 48 BC patients, who were initially diagnosed by 18F-FDG PET/CT, were retrospectively enrolled in this study. LIFEx software was used to extract radiomic features based on PET and CT data. The most useful predictive features were selected by the LASSO (least absolute shrinkage and selection operator) regression and t-test. Radiomic signatures and clinicopathologic characteristics were incorporated to develop a prediction model using multivariable logistic regression analysis. The receiver operating characteristic (ROC) curve, Hosmer-Lemeshow (H-L) test, and decision curve analysis (DCA) were conducted to assess the predictive efficiency of the model | ||
520 | |a RESULTS: In the univariate analysis, the metabolic tumor volume (MTV) was significantly correlated with the expression of AR in BC patients (p < 0.05). However, there only existed feeble correlations between estrogen receptor (ER), progesterone receptor (PR), and AR status (p = 0.127, p = 0.061, respectively). Based on the binary logistic regression method, MTV, SHAPE_SphericityCT (CT Sphericity from SHAPE), and GLCM_ContrastCT (CT Contrast from grey-level co-occurrence matrix) were included in the prediction model for AR expression. Among them, GLCM_ContrastCT was an independent predictor of AR status (OR = 9.00, p = 0.018). The area under the curve (AUC) of ROC in this model was 0.832. The p-value of the H-L test was beyond 0.05 | ||
520 | |a CONCLUSIONS: A prediction model combining radiomic features and clinicopathological characteristics could be a promising approach to predict the expression of AR and noninvasively screen the BC patients who could benefit from anti-AR regimens | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a 18F-FDG PET/CT | |
650 | 4 | |a Androgen receptor | |
650 | 4 | |a Breast cancer | |
650 | 4 | |a Clinicopathological | |
650 | 4 | |a Machine learning | |
650 | 4 | |a Radiomics | |
650 | 7 | |a Androgens |2 NLM | |
650 | 7 | |a Fluorodeoxyglucose F18 |2 NLM | |
650 | 7 | |a 0Z5B2CJX4D |2 NLM | |
650 | 7 | |a Receptors, Androgen |2 NLM | |
700 | 1 | |a Lv, Qingfu |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Bin |e verfasserin |4 aut | |
700 | 1 | |a Yu, Chunjing |e verfasserin |4 aut | |
700 | 1 | |a Sang, Shibiao |e verfasserin |4 aut | |
700 | 1 | |a Deng, Shengming |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t BMC medical imaging |d 2001 |g 23(2023), 1 vom: 17. Juli, Seite 93 |w (DE-627)NLM116251670 |x 1471-2342 |7 nnns |
773 | 1 | 8 | |g volume:23 |g year:2023 |g number:1 |g day:17 |g month:07 |g pages:93 |
856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12880-023-01052-z |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 23 |j 2023 |e 1 |b 17 |c 07 |h 93 |